Back to top

Bull of the Day

The third quarter of fiscal 2010 turned out to be the second consecutive profitable quarter for Genomic Health (GHDX) with an EPS of $0.12, surpassing the Zacks Consensus Estimate of breakeven earnings.

The company's lead product, the Oncotype DX breast cancer test, recorded annualized growth of 17%. Although the colon cancer test launched earlier this year has yet to make a significant contribution to the top line, the situation could improve gradually as the company tries to receive reimbursements.

We are also encouraged by the NCCN guidelines, which could lead to growing awareness among patients and further increase the acceptance of the test. Given these factors we have raised our estimates and upgrade the stock to Outperform.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%